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Background. Colon capsule endoscopy (CCE) represents a noninvasive technology that 
allows visualization of the colon without requiring sedation and air insufflation. A 
second-generation colon capsule endoscopy system (PillCam Colon 2) (CCE-2) was 
developed to increase sensitivity for colorectal polyp detection compared with the first-
generation system. 
Objective. To assess the feasibility, accuracy, and safety of CCE-2 in a head-to-head 
comparison with colonoscopy. 
Design and Setting. Prospective, multicenter trial including 8 European sites. 
Patients: This study involved 117 patients (mean age 60 years). Data from 109 patients 
were analyzed. 
Intervention. CCE-2 was prospectively compared with conventional colonoscopy as 
the criterion standard for the detection of colorectal polyps that are ≥6 mm or masses in 
a cohort of patients at average or increased risk of colorectal neoplasia. Colonoscopy 
was independently performed within 10 hours after capsule ingestion or on the next day. 
Main Outcome Measurements. CCE-2 sensitivity and specificity for detecting patients 
with polyps ≥6 mm and ≥10 mm were assessed. Capsule-positive but colonoscopy-
negative cases were counted as false positive. Capsule excretion rate, level of bowel 
preparation, and rate of adverse events also were assessed. 
Results. Per-patient CCE-2 sensitivity for polyps ≥6 mm and ≥10 mm was 84% and 
88%, with specificities of 64% and 95%, respectively. All 3 invasive carcinomas were 
detected by CCE-2. The capsule excretion rate was 88% within 10 hours. Overall colon 
cleanliness for CCE-2 was adequate in 81% of patients. 
Limitations. Not unblinding the CCE-2 results at colonoscopy; heterogenous patient 
population; nonconsecutive patients. 
Conclusion. In this European, multicenter study, CCE-2 appeared to have a high 
sensitivity for the detection of clinically relevant polypoid lesions, and it might be 
considered an adequate tool for colorectal imaging. 
 
 
Abbreviations: CCE-2, second-generation colon capsule endoscopy; PEG, 
polyethylene glycol. 
INTRODUCTION 
 
Colorectal cancer represents a major cause of morbidity and mortality in Western 
countries.1,2 Although colorectal cancer prevention based on the identification and 
removal of precancerous adenomatous polyps at colonoscopy has been highly effective 
in case-control and randomized studies,3,4 colorectal cancer screening uptake is still 
disappointingly low, especially when compared with the high rate of attendance for 
breast, cervical, and prostate cancer screening programs.5,6 In particular, colonoscopy is 
usually perceived as an invasive and potentially painful procedure, being also affected 
by a small but definite risk of major complications, and even mortality. To improve 
both acceptability and safety, PillCam colon capsule endoscopy (Given Imaging Ltd, 
Yoqneam, Israel) has been pioneered. Colon capsule endoscopy represents a 
noninvasive technique that allows exploration of the colon without requiring sedation 
and air insufflation. When compared with colonoscopy, first-generation colon capsule 
endoscopy demonstrated safety and feasibility as an imaging test for visualizing the 
colorectal mucosa.7 However, the sensitivity of first-generation colon capsule 
endoscopy for clinically meaningful lesions—that is, ≥6 mm polyps or masses—
appeared to be suboptimal as compared with colonoscopy.7 For this reason, a second-
generation colon capsule endoscopy system (CCE-2) has been developed. In particular, 
the frame rate has been increased from 4 to 35 images per second from the first to the 
second generation systems, in order to adequately image the mucosa when the capsule 
is accelerated by peristalsis. The angle of view from each of the two capsule ends also 
has been increased from 156° to 172° for each lens, in order to nearly cover 360° of the 
colon surface. In addition, the new data recorder (DR3) provides alerts (visual and audio 
indications) for procedure activities—such as boost administrations—and it allows real-
time viewing on its liquid-crystal diode display. Up to now, CCE-2 has been tested only 
in one Israeli study, in which sensitivity for polyps ≥6 mm was as high as 89%.8
In this European, multicenter, prospective trial, we aimed to assess the accuracy of 
CCE-2 in detecting patients with polyps ≥6 mm and ≥10 mm or masses, adopting 
colonoscopy as the reference standard. 
 
 
PATIENTS AND METHODS 
 
A total of 8 European sites participated in this prospective study. Recruitment began 
August 28, 2009 and ended July 7, 2010. Patients (18-80 years of age) who were 
scheduled to undergo colonoscopy for either known or suspected colonic disease were 
enrolled in the study. Indications included colorectal cancer screening; personal history 
of colorectal cancer or adenomatous polyps and at least 3 years since last conventional 
colonoscopy; clinical symptoms such as rectal bleeding, positive fecal occult blood test, 
recent change of bowel habits; or positive findings in the colon on GI imaging. Patients 
were excluded from the study for the following reasons: dysphagia or any swallowing 
disorder, congestive heart failure, allergy or other known contraindication to the 
medications used in the study, an increased risk for capsule retention (ie, Crohn’s 
disease, previous abdominal surgeries, ongoing nonsteroidal anti-inflammatory drug 
use), or cardiac pacemaker or other implanted electromedical device. The study was 
approved by every local institutional ethics board (MA-201) and met all criteria put 
forth by the Declaration of Helsinki. All participants signed written informed consent 
before participation in the study. 
 
Second-generation colon capsule endoscopy 
All patients enrolled in this study underwent examination with CCE-2 and a 
conventional colonoscopy procedure on the same or next day. 
The CCE-2 capsule is 11.6 x 31.5 mm in size, slightly bigger than the previous capsule. 
It has two imagers with a much wider angle of view, which has been increased to 172° 
degrees for each imager, allowing nearly 360° coverage of the colon. Furthermore, in 
order to enhance colon visualization and save battery energy, the capsule is equipped 
with an adaptive frame rate. CCE-2 captures 35 images per second when in motion and 
4 images per second when it is virtually stationary. This advanced system for the control 
of capsule image rate is the result of bidirectional communication between the CCE-2 
and the new data recorder. The capsule battery life is at least 10 hours. 
Before the colon capsule endoscopy procedure, patients were instructed to perform the 
colon preparation procedure, which included 4 senna tablets at bedtime 2 days before 
examination day, clear liquid diet the day before examination, and 4 L of polyethylene 
glycol (PEG), split into two doses (one administered on the evening before the 
examination and the second on the morning of examination). After capsule ingestion, 
additional doses of laxatives (sodium phosphate boosters) were administered to 
facilitate capsule propulsion. The timing of administrating the boosts was indicated by 
the data recorder (visual and audio indications). Real-time viewing was eventually used 
by the medical staff to determine the capsule location. If the capsule was not expelled 
approximately 5 hours after the first boost, a bisacodyl suppository was used. Colon 
preparation procedure details are listed in the Appendix. 
Interpretation of the data was performed by investigators who had prior experience with 
small bowel capsule endoscopy and who were specifically trained for colon capsule 
endoscopy. Investigators were blinded to the conventional colonoscopy results. Colon 
cleanliness was graded by using a 4-point scale (excellent or good [adequate], fair or 
poor [inadequate]) for each of the following colonic segments9: cecum, right colon, 
transverse colon, left colon, rectosigmoid colon. An overall colon cleansing grade also 
was evaluated by using the same grading system. The colon capsule procedure was 
considered complete when the colon capsule was naturally expelled. When polyps were 
diagnosed, they were classified with respect to location within the colon, size, and 
morphology (pedunculated, sessile, flat, and depressed). Polyp size was estimated 
during capsule video reading by using the polyp size estimation tool included in the 
RAPID software (Given Imaging Ltd, Yoqneam, Israel). Other lesions such as 
angiomas, diverticula, inflammation, and hemorrhoids were also described but not 
considered for statistical analysis. 
 
 
Colonoscopy 
After the CCE-2 procedure, standard colonoscopy was performed by a physician 
blinded to the results of CCE-2. Colonoscopy was in most cases performed on the same 
day (without any additional preparation), after capsule expulsion or at the latest after 10 
to 12 hours after capsule ingestion. Because of logistical constraints in two centers, 
colonoscopy was performed on the next day and an adjunctive bowel cleansing (2 L 
PEG) was indicated in the evening before the procedure. Colonoscopy was performed 
according to the standard clinical protocol at each participating site by an experienced 
endoscopist. For each colonoscopy, completeness of the procedure was recorded, and 
colon cleansing level at the different segments was graded by using the 4-point scale 
similar to the one used for CCE-2. When polyps were diagnosed, they were classified 
with respect to morphology (pedunculated, sessile, flat, and depressed), location (colon 
segment and distance from anal verge), size (measured in vivo by using open biopsy 
forceps with an 8-mm length as reference), and histology. 
 
 
Statistical methods 
The primary endpoint of the study was to compare the accuracy of CCE-2 versus 
colonoscopy for detection of colorectal polyps ≥6 mm as the largest lesions. The same 
analysis also was performed for the detection of lesions ≥10 mm. The analysis was 
performed according to a per-patient evaluation. Patients without endoscopically 
confirmed polyps ≥6 mm or ≥10 mm were classified as having a negative result at the 
reference standard (standard colonoscopy). Patients were considered as having a 
positive result when at least one polyp ≥6 mm or ≥10 mm was observed at colonoscopy. 
When two or more polyps were detected in the same patient, the largest was considered 
for participant classification; accordingly, patients were classified as positive for polyps 
in the corresponding size range. 
CCE-2 results were reported as positive when a polyp ≥6 mm or ≥10 mm was detected, 
otherwise they were reported as negative. If CCE-2 was positive, and the participant 
was positive for at least one ≥6 mm or ≥10 mm polyp at colonoscopy that was within 
50% of its reference standard measure at CCE-2, the CCE-2 result was considered a true 
positive in that size range. If the CCE-2 result was positive, but the case was classified 
as negative at colonoscopy, it was considered a false positive. 
Sensitivity and specificity along with their exact 95% confidence intervals (CI) were 
calculated according to polyp size. No unblinding of colon capsule endoscopy results at 
colonoscopy was carried out. This was because of the very short interval between CCE-
2 and colonoscopy procedures, preventing an adequate reading of the CCE-2 
examination. Adverse events for both procedures were reported. 
For the sample size calculation, considering colonoscopy as the reference standard, 
colon capsule endoscopy was assumed to have an 84% sensitivity (with the precision of 
± 16%) (according to the interim analysis of ongoing studies) in detecting patients with 
polyps equal to or larger than 6 mm. In addition, the prevalence of polyps equal to or 
larger than 6 mm was assumed to be 40% in an enriched population. In order to 
maintain that hypothesis as well as the type I error (α) of 5% and power (= 1-β) of 80%, 
the required sample size was estimated to be 103. Adding a dropout rate of 13% 
resulted in a total study size of 117 patients. 
 
 
RESULTS 
 
The 8 participating centers enrolled 117 patients (mean ± SD age 60 ± 9 years; 72 men). 
Clinical indications for colonoscopy are provided in Table 1. Eight of 117 patients 
(6.8%) were excluded from the efficacy analysis for the following reasons: inability to 
swallow the capsule (1 case), technical failure of the data recorder (2 cases), and capsule 
technical failure (2 cases). In two cases, the capsule remained in the cecum during the 
entire procedure, and one patient withdrew consent to proceed with the procedure after 
7:44 hours. Therefore, a total of 109 patients were included in efficacy analysis. 
 
 
Colon cleansing level 
The overall cleansing level was adequate in 81% (95% CI, 73%-88%) of patients at 
CCE-2. In detail, it was considered adequate in the cecum in 67% of patients, in the 
ascending colon in 75%, in the transverse colon in 78%, in the descending colon in 
86%, and in the rectum in 63%. The overall cleanliness for colonoscopy was adequate 
in 92% of patients. 
 
 
Colon capsule endoscopy egestion rate 
Overall, 88% of the capsules were naturally egested within 10 hours—85% and 68% 
within 8 and 6 hours after ingestion, respectively. In 3 (2.6%) patients, the CCE-2 
capsule impacted against a tumor and was retrieved during colonoscopy or surgery. 
Because of logistical constraints of the study, colonoscopy was performed no later than 
8 to 10 hours after capsule ingestion even if the capsule was still active (4 patients, 4%). 
Conventional colonoscopy was completed in all but two (1.7%) cases (tumor in the 
descending colon). Both of the procedures (CCE-2 and conventional colonoscopy) 
identified the tumor and estimated it as ≥10 mm. 
 
 
Colon capsule endoscopy accuracy 
At colonoscopy, a total of 45 patients (41.3%) had at least one polyp ≥6 mm. Thirty-two 
patients (29.3%) had at least one polyp that was ≥10 mm. Per-patient sensitivity of 
CCE-2 for ≥6 mm and ≥10 mm polyps was 84% (95% CI, 74%-95%) and 88% (95% 
CI, 76%-99%), respectively (Table 2). All 3 cancers (2 in the descending colon and 1 in 
the sigmoid colon) detected by colonoscopy were also identified by CCE-2. Of the 7 
false-negative cases at CCE-2, a size mismatch (ie, measured as <6 mm at CCE-2) 
occurred in 3 patients, with a polyp ≥6 mm at colonoscopy (6-9 mm, 2 cases; ≥10 mm, 
1 case), whereas 4 were actually missed by CCE-2. When we assessed the 4 lesions, 2 
cases were later identified by re-reading as polyps missed by the reader (Fig. 1). In one 
case, the capsule was retrieved in the ascending colon during colonoscopy while it was 
still working at 9:44 hours after ingestion. The polyp was distal in the sigmoid colon, 
and, thus, it was not visualized. The last case should be considered a real falsenegative 
case (Table 3). 
When restricting our analysis only to neoplastic lesions, 39 (36%) and 30 (28%) 
patients were seen with at least one adenoma ≥6 mm and ≥10 mm, respectively. CCE-2 
correctly classified 35 and 28 of these patients, corresponding to a detection rate for ≥6 
mm and ≥10 mm neoplasia of 90% (95% CI, 80%-99%) and 93% (95% CI, 84%-
100%), respectively. CCE-2 specificity for detection of polyps ≥6 mm and ≥10 mm was 
64% (95% CI, 52%-76%) and 95% (95% CI, 90%-100%), respectively. When merging 
the truepositive and false-positive results, the cumulative CCE-2 positivity rate was 
56% and 29% for polyps ≥6 mm and ≥10 mm, respectively. 
When including diminutive (ie, <5 mm) polyps in our analysis, the overall polyp 
detection rate (regardless of size) at colonoscopy and CCE-2 was 84% and 81%, 
respectively. 
The low specificity observed in this study for ≥6-mm polyps was explained by a 
substantial rate of false-positive polyps because of size mismatch. As shown in Table 4, 
20 (80%) of the 25 false-positive cases at CCE-2 (6-9 mm, 21 cases; ≥10 mm, 4 cases) 
were because of size mismatching (ie, <6 or <10 mm polyp at colonoscopy measured as 
≥6 or ≥10 mm at CCE-2) (Fig. 2). No polyp was detected at colonoscopy in the 
remaining 5 cases in which CCE-2 detected at least one ≥6-mm polyp (Fig. 3). The 
overall colon capsule endoscopy accuracy (mean between sensitivity and specificity) for 
≥6-mm and ≥10-mm lesions appeared to be 76% and 92%, respectively. 
In addition to polyps or masses, CCE-2 detected other diseases. Colonoscopy detected 
diverticulosis and erythema/ inflammation in 32 and 11 patients, respectively, and CCE-
2 identified 24 and 4 of these patients, respectively. Furthermore, CCE-2 detected 
diverticulosis and erythema/inflammation that were not diagnosed by colonoscopy in an 
additional 27 and 7 patients, respectively. 
In 23% of cases, the video interpretation took ≤30 minutes, in 47% of cases ≤40 
minutes, and in 71% of cases ≤50 minutes. 
 
 
Adverse events 
A total of 8 mild to moderate adverse events were reported in 117 patients (6.8%), and 
these resolved spontaneously within 24 to 48 hours. In 5 of these, adverse events were 
related to bowel preparation and included vomiting, nausea, and abdominal pain. Two 
patients experienced fatigue because of the long capsule procedure. One patient 
experienced severe abdominal pain during conventional colonoscopy.  
One patient experienced a severe adverse event not related to colon capsule endoscopy: 
a colon perforation after polypectomy occurred. The patient was treated endoscopically, 
was hospitalized, received medical treatment, and the adverse event resolved. 
 
 
DISCUSSION 
 
Our prospective, multicenter study showed a sensitivity as high as 84% and 88% for ≥6-
mm and ≥10-mm polyps, respectively, when comparing CCE-2 with colonoscopy. 
These results are well in line with the colon capsule endoscopy–sensitivity values of 
89% and 88% assessed in the previous Israeli study,8 confirming the high colon capsule 
endoscopy sensitivity for clinically relevant lesions. Of note, the mean age of the 
patients included in our study—that is, 60 years—is more similar to that of an 
unselected population referred for colonoscopy, as compared with the previous Israeli 
study in which only patients aged <57 years were included.8 The sensitivity of the CCE-
2 for ≥6-mm lesions—consistently superior to 80% in these first two studies—seems to 
be higher than the 68% value estimated in a recent meta-analysis for firstgeneration 
colon capsule endoscopy,7 suggesting the superiority of the new device as compared 
with the previous one. However, a direct comparison between first-generation and 
second-generation colon capsule endoscopy was outside the purposes of our analysis, so 
conclusive statements cannot be made. Moreover, all 3 cases of malignancy were 
detected by CCE-2 in our study, as was the one case of cancer in the Eliakim et al8 
series, whereas a suboptimal sensitivity for cancer was described with first-generation 
colon capsule endoscopy.7 CCE-2 sensitivity would also appear to compare favorably 
with a similarly noninvasive imaging test, represented by CT colonography, for which a 
90% sensitivity for large polyps was reported.10 Presumably, the high sensitivity of 
CCE-2 in our study as well as in the previous series,8 may be a result of the 
technological improvements of the device, namely the higher frame rate and the larger 
angle of view of the two lenses. A further reason for the high sensitivity of the CCE-2 
may be the relatively high degree of adequate level of bowel preparation achieved in the 
present series, an intimate association between colon capsule endoscopy sensitivity and 
level of preparation having already been shown.11 The 81% level of good to excellent 
preparation shown in our series is well in line with the 78% reported in the Israeli study 
as well as with the 78% reported with the same regimen in a previous study with first-
generation colon capsule endoscopy.8,12 Such a high rate of adequate bowel preparation 
is substantially higher than the median value of 72% reported in the metaanalysis of the 
studies with first-generation colon capsule endoscopy7 in which such a regimen had not 
been used. The main improvements of the regimen adopted in the present study are 
represented by a more balanced splitdose of PEG solution (2 L the evening before and 2 
L on the day of capsule ingestion) and a low dose of sodium phosphate boosters. Of 
note, the low dose of sodium phosphate did not hamper the colon capsule endoscopy 
excretion rate, an adequate 88% rate being observed within 10 hours (ie, when study 
colonoscopy was planned). It also may be speculated that the new feature of data 
recorder alerts for procedure activities enhanced compliance with the procedure regimen 
and thus contributed to adequate colon cleansing. It also should be emphasized that only 
2 of the 7 false-negative cases were related to a real miss by CCE-2. Indeed, in 3 cases, 
CCE-2 identified the ≥6-mm polyp, although measuring it as <6 mm, whereas in two 
cases a perceptual error by the reader occurred. 
An apparently suboptimal specificity of CCE-2 also has been observed in our study, 
resulting in a low positive predictive value for post-CCE-2 colonoscopy. This would 
appear quite unexpected when dealing with an endoscopic procedure, such as colon 
capsule endoscopy, a virtually 100% specificity for polypoid lesions (ie, irrespectively 
from histology) being reported with other endoscopic procedures, such as flexible 
sigmoidoscopy or colonoscopy.13 There are at least two main reasons to explain such a 
result. First, colonoscopy is an imperfect reference standard with a suboptimal 
sensitivity, especially for 6- to 9-mm polyps.14,15 When considering that in our study, as 
well as in previous colon capsule endoscopy studies,7,8 post-CCE colonoscopy was 
performed without unblinding of CCE results, it cannot be excluded that apparently 
false-positive results at CCE were in fact false-negative results at colonoscopy. To 
overcome this bias, unblinding of CCE-2 results at post-CCE-2 colonoscopy or a 
different study methodology may be needed. One improvement could be to have only 
patients with CCE-2–positive results referred to colonoscopy after CCE-2 reading. 
Second, Table 4 clearly shows that a substantial rate of falsepositive results is related to 
a misclassification of <6 mm polyps at colonoscopy as ≥6 mm at CCE-2. When these 
misclassified polyps are considered as true positive results, specificity for any polyp 
would be as high as 92%. Although this may question the overall accuracy of colon 
capsule endoscopy in categorizing lesions as above or below a predefined cut-off, it also 
should be emphasized that a false-positive result based on a <6 mm polyp at post-CCE 
colonoscopy is much different from a false-positive result with no polyp finding at post-
CCE colonoscopy. Considering that the avoidance of polypectomy for <6-mm lesions is 
still controversial because of a definite prevalence of advanced neoplasia within these 
lesions,16 the clinical relevance of such size mismatching is likely to be marginal. 
Moreover, the new polyp size estimation tool that is now embedded in the RAPID 
software has not been validated, and potential improvements in reading software may be 
expected to allow a more precise polyp size assessment, reducing the observed 
mismatch rate. It also could be argued that if we had included in our analysis the 
diminutive polyps (<6 mm) (their removal after noninvasive diagnosis remains 
controversial), the post-CCE-2 colonoscopy rate would have been further increased 
from the 56% assessed. This would raise some concern regarding the potential cost 
effectiveness of this approach. However, it is intrinsic in the choice of a noninvasive 
approach to find a balance between a higher acceptability and a slight reduction of 
clinical efficacy. 
  
 
 
Our study also confirmed the feasibility and safety of the CCE-2 procedure. A complete 
visualization of the colo-rectal mucosa was achieved in the vast majority of patients, 
and no major side effects were reported. 
There are limitations to the present analysis. We presented accuracy data for polyps ≥6 
mm with the implicit assumption that post-CCE-2 polypectomy may lead to colorectal 
cancer prevention. However, such a hypothesis has been challenged by a recent 
epidemiological study showing no colorectal cancer incidence or mortality reduction 
after colonoscopy in the right side of the colon.17 We adopted colonoscopy as the 
reference standard, despite that the need for an enhanced reference standard has been 
clearly shown by previous studies on CT colonography.18 Unlike CT colonography 
studies,10 the polyp matching algorithm was based only on polyp size and not location. 
The accuracy of colon capsule endoscopy in polyp localization needs to be validated. 
Also in the present study, CCE-2 was tested in an enriched population, resulting in a 
very high post-CCE-2 colonoscopy rate (ie, total CCE-2 positivity rate). However, it is 
expected that this rate would be substantially lower in settings with a low prevalence of 
neoplasia (ie, screening), where noninvasive techniques may be expected to play a 
major role because of their higher acceptability. Finally, the patient population included 
in the present series is heterogenous, suggesting that at the moment these results cannot 
be projected to a screening population. 
In this European multicenter study, CCE-2 appeared to be highly sensitive in detecting 
clinically relevant polypoid lesions, expanding the generalizability of the findings of the 
previous Israeli study.8 When coupling this evidence with the feasibility and safety of 
colon capsule endoscopy, colon capsule endoscopy may be considered as an adequate 
tool to visualize the colorectal mucosa. The apparently suboptimal colon capsule 
endoscopy specificity is likely to be related to the study methodology or polyp size 
mismatching, with the clinical impact likely to be marginal. 
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Table 1. Indication for colonoscopy* 
Indication, no. (%) 
Personal history of polyps/positive findings 52 (44) 
Recent change in bowel habits 27 (23) 
Colorectal cancer screening 25 (21) 
Rectal bleeding/hematochezia 23 (20) 
Abdominal pain 18 (15) 
Positive fecal occult blood test 7 (6) 
*Some patients were enrolled because of more than one 
indication. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Accuracy characteristics for detection of patients with at least                
one lesion >6 mm or >10mm 
 Colonoscopy PillCam Colon 2 
Polyp size, mm Prevalence, no. (%) 
Sensitivity,% 
(95% CI) 
Specificity,% 
(95% CI) 
≥6 mm 45 (41) 84 (74-95) 64 (52-76) 
≥10 mm 32 (29) 88 (76-99) 95 (90-100) 
CI, Confidence interval. 
 
 
 
Table 3. Real false-negative lesions ≥6 mm (excluding those related to size 
mismatching between CCE-2 and colonoscopy) 
Polyp size by colonoscopy Location Comment 
80 mm Cecum Independent, unblinded review detected the polyp 
12 mm Ascending Independent, unblinded review detected the polyp 
20 mm Descending-sigmoid 
CCE-2 was retrieved in the 
ascending colon during 
colonoscopy 9:44 hours 
after ingestion. The polyp 
was in the sigmoid colon 
and, thus, was not 
visualized 
7 mm Ascending False negative 
CCE-2, PillCam Colon 2 second-generation capsule endoscopy system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. False-positive lesions ≥ 6 mm 
Polyp size by 
colonoscopy, mm 
Polyp size by 
capsule, mm Comment 
— 9 False positive 
— 9 False positive 
— 6 False positive 
— 7 False positive 
— 8 False positive 
4 7 Size mismatch 
2 8 Size mismatch 
3 6 Size mismatch 
3 7 Size mismatch 
3 6 Size mismatch 
5 6 Size mismatch 
5 6 Size mismatch 
4 7 Size mismatch 
3 6 Size mismatch 
3 7 Size mismatch 
5 6 Size mismatch 
5 6 Size mismatch 
3 7 Size mismatch 
4 6 Size mismatch 
4 6 Size mismatch 
4 6 Size mismatch 
4 12 Size mismatch 
5 12 Size mismatch 
8 10 Size mismatch* 
7 10 Size mismatch* 
*Only at >10 mm cut-off. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. False-negative cases: two cases of lesions missed by PillCam Colon 2 capsule 
endoscopy (CCE-2). A, An 80-mm polyp visualized by colonoscopy in the cecum. C, A 
12-mm polyp visualized by colonoscopy in the ascending colon. Polyps missed by the 
investigators at CCE-2 were later identified by an unblinded reviewer not associated 
with the study (B, D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. False-positive cases because of size mismatch. A, PillCam Colon 2 capsule 
endoscopy (CCE-2) identified a 6-mm polyp that at colonoscopy was measured as 5 
mm (B). C, A 10-mm polyp by CCE-2: the size estimation at colonoscopy was 8 mm 
(D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. False-positive cases (polyps missed by colonoscopy). Images of 3 false-
positive cases: 9-mm polyp (A), 7-mm polyp (B), and 8-mm polyp (C). PillCam Colon 
2 capsule endoscopy identified these polyps that were missed by colonoscopy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX: PILLCAM COLON 2 PREPARATION REGIMEN 
 
Day Timing Procedure 
Day 2 All day At least 10 glasses of water 
 Bedtime 4 senna tablets (12 mg each) 
Day 1 All day Clear liquid diet 
 Evening 2 L PEG 
Examination day Morning 2 L PEG 
 About 10 AM Capsule ingestion* 
 First boost Upon small bowel detection 
30 mL sodium phosphate 
& 1 L water 
 Second boost 3h after first boost 
25 mL sodium phosphate 
& 0.5 L water 
 Suppository 2 h after second boost 10 mg bisacodyl 
PEG, Polyethylene glycol. 
*20 mg domperidone tablet if capsule delayed in stomach >1 h. 
 
